BillionToOne Q1 Revenue Jumps 84% to $108.4M, Raises 2026 Guidance to $450M-$465M
BLLN sits 29% above its 52-week low of $61.96 on elevated volume (1.9× avg).
Summary
BillionToOne reported exceptionally strong first-quarter 2026 financial results, with total revenue surging 84% year-over-year to $108.4 million and a significant swing to net income of $18.0 million, or $0.34 per diluted share, from a loss in the prior year. This robust performance, which includes a 44% increase in tests delivered and improved gross margins, builds on the strong 2025 results noted in their recent 10-K, indicating continued momentum. The company also raised its full-year 2026 revenue guidance to a range of $450 million to $465 million, representing 48% to 52% growth over 2025, signaling continued confidence in its growth trajectory. The recent launch of Unity ConfirmTM and expansion of payor contracts further underscore the operational momentum. This news is highly material as it indicates strong execution, increasing profitability, and an improved outlook, likely driving positive investor sentiment.
At the time of this announcement, BLLN was trading at $80.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $61.96 to $138.70. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.